Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robb Wesselingh

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis and Related Disorders|December 15, 2020
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemicLouise Rath, Minh Viet Bui, Julian Ellis, et al.
European Journal of Neurology|April 23, 2022
Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis ConsortiumSarah Griffith, Robb Wesselingh, James Broadley, et al.
Multiple Sclerosis and Related Disorders|December 3, 2023
Neutropaenia complications from Ocrelizumab and Rituximab treatmentVenus Pang, Nabil Seery, Robb Wesselingh, et al.
Journal of the Neurological Sciences|June 19, 2026
Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remissionMeltem Karadeniz, Robb Wesselingh, Padmakrishnan C Jayakrishnan, et al.
British Journal of Haematology|July 28, 2025
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapyChristina Kazzi, Ty Simpson, Miriam Wronski, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2024
CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective studyMastura Monif, Richard P Sequeira, Andrea Muscat, et al.
Multiple Sclerosis and Related Disorders|March 15, 2026
Characterising executive functioning in the chronic phase of autoimmune encephalitis: A study by the Australian autoimmune encephalitis consortiumKatherine Y Ko, Nabil Seery, Sarah Griffith, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis and Related Disorders|December 15, 2020
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemicLouise Rath, Minh Viet Bui, Julian Ellis, et al.
European Journal of Neurology|April 23, 2022
Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis ConsortiumSarah Griffith, Robb Wesselingh, James Broadley, et al.
Multiple Sclerosis and Related Disorders|December 3, 2023
Neutropaenia complications from Ocrelizumab and Rituximab treatmentVenus Pang, Nabil Seery, Robb Wesselingh, et al.
Journal of the Neurological Sciences|June 19, 2026
Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remissionMeltem Karadeniz, Robb Wesselingh, Padmakrishnan C Jayakrishnan, et al.
British Journal of Haematology|July 28, 2025
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapyChristina Kazzi, Ty Simpson, Miriam Wronski, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2024
CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective studyMastura Monif, Richard P Sequeira, Andrea Muscat, et al.
Multiple Sclerosis and Related Disorders|March 15, 2026
Characterising executive functioning in the chronic phase of autoimmune encephalitis: A study by the Australian autoimmune encephalitis consortiumKatherine Y Ko, Nabil Seery, Sarah Griffith, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Pageof 6